Related Articles

• Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
• Efficacy of tyrosine kinase inhibitors in non‑small‑cell lung cancer patients undergoing dose reduction and those with a low body surface area
• The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR‑TKIs but is not an indication of acquired resistance to EGFR‑TKIs in NSCLC patients with EGFR mutations
• Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
• Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors